Clinical Trials Logo

Clinical Trial Summary

Quantification of the metabolic rate of glucose from Dynamic Whole-Body PET examinations requires measurements of the time course of the radioactivity concentrations in arterial blood by blood sampling, and in the tissue of interest by dynamic PET. Invasive arterial blood sampling cannot be part of a standard examination, and therefore the blood samples need to be replaced by activity concentrations derived from the PET images, usually from small volumes in the descending aorta or left ventricle. Newly developed scanner software (Siemens) allows automated CT-based identification of blood pool regions and extraction of an image-derived blood input function from the corresponding PET data. However, this automated method needs validation, as it could be prone to systematic errors caused by limited spatial resolution, patient movement, and image reconstruction. We will use invasively measured arterial blood samples as a reference for validation of methods to extract non-invasive PET image-derived input functions and quantify any systematic errors that could propagate to the resulting parametric images.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04660279
Study type Interventional
Source Aarhus University Hospital
Contact
Status Completed
Phase N/A
Start date January 1, 2020
Completion date December 31, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04555642 - Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
Recruiting NCT05004961 - The Performance of Multi-tracer Multimodality PET in Lymphoma
Recruiting NCT05188872 - Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE N/A
Recruiting NCT04983095 - Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer Phase 3
Recruiting NCT05610098 - Gene Expression Profiles in Spinal Tuberculosis.
Recruiting NCT04416165 - Comparison of FDG and FAPI in Patients With Various Types of Cancer N/A
Recruiting NCT04750772 - Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer N/A
Recruiting NCT04831541 - 68Ga-PSMA-11 PET/CT in Patients With Various Types of Cancer Early Phase 1
Recruiting NCT06188468 - ImmunoPET Targeting Trophoblast Cell-surface Antigen 2 (Trop-2) in Solid Tumors N/A
Recruiting NCT06017973 - The Role of Imaging in the Diagnosis, Management and Prognosis of Possible Non-convulsive Status Epilepticus N/A
Recruiting NCT03830242 - Diagnostic Significance of FDG PET/CT Dynamic Imaging in Detecting Metastatic Lymph Nodes With Papillary Thyroid Cancer. N/A
Recruiting NCT06387381 - 68Ga-PSFA PET Imaging in Patients With PSMA/FAP Positive Disease Early Phase 1
Recruiting NCT05506566 - 68Ga-FAP-CHX PET/CT : Dosimetry and Preliminary Clinical Translational Studies Phase 1/Phase 2
Not yet recruiting NCT04367948 - Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma N/A
Recruiting NCT05757804 - Study of 18F-0502B PET Imaging Targeting α-synuclein in the Diagnosis of α-synuclein-related Diseases
Completed NCT05392205 - Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer N/A
Completed NCT03741231 - 18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
Completed NCT01035164 - Evaluation of ZK 6032924 in Probable Alzheimer's Disease Patients Versus Healthy Volunteers and the Radiation Dosimetry of ZK 6032924 in Healthy Volunteers Phase 1
Completed NCT03107663 - ⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma Phase 1
Recruiting NCT03636607 - Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma N/A